Source comparison
Limitations of This Comparison
Several structural limitations constrain any honest reading of the tesamorelin–CJC-1295 literature: Asymmetric evidence base. One compound has multiple Phase 3 RCTs and regulatory review; the other has two small early-phase studies and discontinued development
This comparison does not assign a generated winner or score.
- Several structural limitations constrain any honest reading of the tesamorelin–CJC-1295 literature:
- Asymmetric evidence base. One compound has multiple Phase 3 RCTs and regulatory review; the other has two small early-phase studies and discontinued development. They cannot be weighed on the same scale.
- Surrogate vs. outcome endpoints. CJC-1295’s human data are entirely GH/IGF-1 surrogates; tesamorelin’s are hard imaging endpoints. Surrogate improvement does not guarantee clinical benefit.
- Population specificity. Tesamorelin’s trials are in people with HIV; effects and safety may differ in other populations, and CJC-1295’s tiny studies were in healthy volunteers.
- The DAC / no-DAC ambiguity. “CJC-1295” is not one molecule, and much popular discussion blurs the two forms.
- Research-chemical identity gap. Material sold outside trials is of unverified identity and purity; even a perfectly designed study using such material would be studying an undefined input. Trial data are not product data.
- No head-to-head trial. The most-wanted comparison simply has not been run.